Stockscreener 앱 받기
56.91
3.56%
-2.10
시간 외 거래:
56.83
-0.08
-0.14%
Veradermics Inc 주식(MANE)의 최신 뉴스
Veradermics to present hair loss treatment data at AAD meeting By Investing.com - Investing.com South Africa
Veradermics Announces Presentations on VDPHL01 and Patient Experi - The National Law Review
Veradermics to present hair loss treatment data at AAD meeting - Investing.com
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting - Business Wire
Veradermics Inc (MANE) Financial Ratios - Investing.com India
Veradermics (MANE) Stock Analysis Report | Financials & Insights - Benzinga Japan
Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance
MANE Should I Buy - Intellectia AI
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals - simplywall.st
Dermatology drug maker Veradermics set for Miami investor spotlight - Stock Titan
Veradermics to Participate in Upcoming March Investor Conferences - Business Wire
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com South Africa
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com Canada
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Biotech IPO Market Thaws: Eikon, Agomab, SpyGlass and Veradermics Lead Billion-Dollar Revival - geneonline.com
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all - statnews.com
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - BioSpace
Veradermics completes $294.8 million IPO with full underwriter option exercise - Investing.com
Veradermics CEO has a great hair day with 122% pop in IPO - Endpoints News
Hair regrowth biotech raises $256m in ‘upsized’ IPO - longevity.technology
Veradermics’ IPO raises $256M in stellar NYSE debut - Hartford Business Journal
Veradermics Raises $256 Million in Upsized Initial Public Offering - Pharmaceutical Executive
A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma
MANE Forecast — Price Prediction for 2026. Should I Buy MANE? - Intellectia AI
Veradermics announces pricing of upsized IPO - The Pharma Letter
Eikon, Veradermics close IPOs, as Salspera joins queue - pharmaphorum
Veradermics stock soars 118% in NYSE debut after upsized IPO By Investing.com - Investing.com India
Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO - Law360
Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO - Smartkarma
Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss - MedCity News
Veradermics prices upsized IPO at $17 per share, raises $256.3 million - Investing.com Nigeria
Veradermics, Dermatology-Focused Biopharma Developing Extended-Release Oral Minoxidil for Pattern Hair Loss, Files for NYSE IPO - TradingView
MANE Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Hair Loss Firm Veradermics Jumps 124% After $256 Million IPO - Bloomberg
No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. - Barron's
Soaring Veradermics IPO Shows Investor Interest In Hair-Loss Companies Isn’t Thinning - Crunchbase News
Veradermics stock soars 118% in NYSE debut after upsized IPO - Investing.com
Veradermics stock surges on public debut (MANE:NYSE) - Seeking Alpha
1.20%
0.06%
자본화:
|
볼륨(24시간):